Vaxil Bio

Vaxil Bio EBITDA per Employee

EBITDA per Employee of Vaxil Bio (VXL.V) as of Oct 17, 2026.

EBITDA per Employee

-CAD

Last updated:

EBITDA per Employee of Vaxil Bio is 2026 - CAD. EBITDA per Employee of Vaxil Bio was 2025 - CAD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaxil Bio Stock analysis

What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaxil Bio stock

On Eulerpool you can find the complete historical development of EBITDA per Employee Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Vaxil Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Vaxil Bio

All Key Metrics — Vaxil Bio